South African GASTROENTEROLOGY Review | Volume 17 Issue 3 2019

DIFFERENT PEOPLE, DIFFERENT CHOICES. S3 PENTASA ® SACHETS 1 g. Each sachet contains 1 g mesalazine. Reg. No.: 43/11/0013. S3 PENTASA ® SACHETS 2 g. Each sachet contains 2 g mesalazine. Reg. No.: 43/11/0014. S3 PENTASA ® 1 g Suppositories. Each suppository contains 1 g mesalazine. Reg. No.: A40/11/0374. S3 PENTASA ® 500 mg Tablet. Each tablet contains 500 mg mesalazine. Reg. No.: 33/11/0088. S3 PENTASA ® 1 g ENEMA. Each 100 ml rectal suspension contains 1 g mesalazine. Reg. No.: 44/11/0888. NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION: FERRING (Pty.) Ltd. Route 21 Corporate Park, 6 Regency Drive, Irene Ext 30. Pretoria, South Africa. Tel: +27 12 345 6358 Fax: +27 12 345 1156 . www.ferring.co.za. PENTASA, FERRING, and the FERRING logo are registered trademarks of Ferring B.V. For full prescribing information please refer to the package insert approved by the medicines regulatory authority. 2019/012 Date of preparation: February 2019. PENTASA ® 1 g ENEMA Ulcerative Proctosigmoiditis & Left-sided Colitis PENTASA ® 1 g SUPPOSITORIES Ulcerative Proctitis PENTASA ® SACHETS Ulcerative Colitis & Crohn’s Disease PENTASA ® 500 mg TABLETS Ulcerative Colitis PENTASA ’s different dosage forms & strengths allow you to choose the best fit for your patient. PENTASA ® prolonged released granules Mesalazine is released throughout the GI tract? YES 1,2 Release of mesalazine at all pH values in the GI tract? YES 1 Does diarrhoea affect the release of mesalazine? * YES 3 Any peak plasma concentrations of mesalazine? ✗ NO 4 May be taken with or without food? YES 1,2 *Although the disposition from Pentasa ® is impaired in case of diarrhoea, the changes were not substantial, and the disposition remains rather favourable. References: 1. Hardy JG, Harvey WJ, Sparrow RA, et al. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa ® ) in the gastrointestinal tract using gamma scintigraphy. J Clin Pharmacol. 1993;33:712-718. 2. Wilding IR. A scintigraphic study to evaluate what happens to Pentasa ® and Asacol ® in the human gut. Practical Gastroenterology. Suppl to November 1999:1-8. 3. Rijk MCM, van Schaik A, Van Tongeren JHM. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea. Scand J Gastroenterol 1992;27(10):863-868. 4. Christensen LA, Fallingborg J, Abildgaard K, et al. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther. 1990;4:523-533. BENEFITS OF PENTASA ® ORAL FORMULATIONS